These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11066473)

  • 1. Creutzfeldt-Jakob disease: the problem of recipient notification.
    DuVal G
    J Law Med Ethics; 1997; 25(1):34-41, 3. PubMed ID: 11066473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informing a recipient of blood from a donor who developed Creutzfeldt-Jakob disease: the characteristics of information that warrant its disclosure.
    Steinberg D
    J Clin Ethics; 2001; 12(2):134-40. PubMed ID: 11642064
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment: dilemmas of dementia.
    Dodd RY
    J Clin Ethics; 2001; 12(2):141-2. PubMed ID: 11642065
    [No Abstract]   [Full Text] [Related]  

  • 4. Ethical analysis of communicating the risk of iatrogenic Creutzfeldt-Jakob disease.
    Shalowitz DI; Barnosky A; Smith LB
    Infect Control Hosp Epidemiol; 2009 Aug; 30(8):805-6. PubMed ID: 19591583
    [No Abstract]   [Full Text] [Related]  

  • 5. Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: integrating science, legal duties and ethical mandates.
    Caulfield T; Dossetor J; Boshkov L; Hannon J; Sawyer D; Robertson G
    CMAJ; 1997 Nov; 157(10):1389-92. PubMed ID: 9371070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment: limiting toxic information.
    Howe EG
    J Clin Ethics; 2001; 12(2):143-9. PubMed ID: 11642066
    [No Abstract]   [Full Text] [Related]  

  • 7. Blood recipients and CJD: to notify or not to notify, that is the question.
    Sibbald B
    CMAJ; 1998 Oct; 159(7):829-31. PubMed ID: 9805032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pressure grows over US blood ban.
    Goodman S
    Nature; 2001 Aug; 412(6846):467. PubMed ID: 11484010
    [No Abstract]   [Full Text] [Related]  

  • 9. The quandary of Creutzfeldt-Jakob disease.
    Larke B
    CMAJ; 1998 Oct; 159(7):789-92. PubMed ID: 9805025
    [No Abstract]   [Full Text] [Related]  

  • 10. Creutzfeld-Jakob disease: the Grace General Hospital experience.
    Pauls F; Hayes J; Read J
    Leadersh Health Serv; 1996; 5(6):42-3. PubMed ID: 10163983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revised precautionary measures to reduce the possible transmission of Creutzfeldt-Jakob disease (CJD) by blood and blood products; guidance document; availability--FDA. Notice.
    Fed Regist; 1997 Sep; 62(184):49694-5. PubMed ID: 10173801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More patients should be excluded from being tissue donors.
    Zeidler M; Brown P
    BMJ; 1998 Apr; 316(7138):1170-1. PubMed ID: 9552975
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential liability for transfusion-associated AIDS.
    Miller PJ; O'Connell J; Leipold A; Wenzel RP
    JAMA; 1985 Jun; 253(23):3419-24. PubMed ID: 3889395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing times ahead -- if you were incubating "human BSE", would you want to know?
    Day M
    New Sci; 1999 Jan; 161(2170):5. PubMed ID: 11657933
    [No Abstract]   [Full Text] [Related]  

  • 15. Creutzfeldt-Jakob disease: implications for growth hormone deficient children.
    Preece MA
    Neuropathol Appl Neurobiol; 1986; 12(5):509-15. PubMed ID: 3537832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notifying patients exposed to blood products associated with Creutzfeldt-Jakob disease: theoretical risk for real people.
    King SM; Watson H; Heurter H; Ricketts M; Elsaadany S
    CMAJ; 1998 Oct; 159(7):771-4. PubMed ID: 9805022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creutzfeldt-Jakob disease: a problem for tissue donation.
    Bredehorn T; Eichhorst A; Tullo A; Duncker G
    Transplant Proc; 2002 Sep; 34(6):2349-50. PubMed ID: 12270432
    [No Abstract]   [Full Text] [Related]  

  • 18. Variant Creutzfeldt-Jakob disease and prions in the blood supply.
    Rohwer RG; Drohan W
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):84, 87, 131. PubMed ID: 16163166
    [No Abstract]   [Full Text] [Related]  

  • 19. Creutzfeldt-Jakob disease and blood products: FDA policy.
    Fratantoni JC
    Biologicals; 1998 Jun; 26(2):133-4. PubMed ID: 9811520
    [No Abstract]   [Full Text] [Related]  

  • 20. Variant Creutzfeldt-Jacob disease - the availability of a screening test will be the beginning, not the end, of difficult transfusion-related issues.
    Sandler SG
    Curr Opin Hematol; 2006 Nov; 13(6):445-6. PubMed ID: 17053456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.